On June 24th NOVADAQ presented at the JMP Securities Healthcare Conference. My apologies for not alerting ahead of the talk, but it is archived on the company site.
This is the first I have listened to the Vice President of Operations, Roger Deck, as presenter. The talk was fairly usual in terms of information and format as compared to others given lately. Though not quite as polished as Arun, Roger was more than competent as a spokesperson.
One item that got my attention was that there has been a marked rise in Firefly utilization over last two months due to its increased use in cholecystectomy. (I still think a new, full-color, enhanced Firefly will happen soon. Just look at the difference between the Pipoint and Firely slides.)
On the Lifecell saga, talks continue, Lifecell is anxious to extend the agreement and is open to terms more favorable to Novadaq. However, Novadaq isn’t convinced Lifecell management is as aligned with with them now as they were in the past.
Pressure is still being applied as evidenced from the talk:
Lifecell has done a great job at getting into plastic surgery but that’s a relatively small market. We could get much broader penetration within a hospital to take advantage of lots of other opportunities that they haven’t really worked on so far.